Increased support for legalization of cannabis is a major factor that drives the growth of cannabis market. According to the data from National pollster Gallup, support for nationwide legalization of cannabis is 60% in 2016 poll, up from 25% in 1995. Four more states legalized recreational cannabis last November, with a total of eight states. While cannabis for medical use is now legal in 28 states. Increased spending on recreational cannabis is another driver of growth. Dispensaries in Colorado alone sold $1.3 billion of legal cannabis in 2016, up from $996 million in 2015.

Vinergy Resources Ltd. (OTCQB: VNNYF) (CSE: VIN.CN) in conjunction with its proposed acquisition of MJ BioPharma (announced December 14, 2016) is pleased to announced yesterday that, "as a part of the Company's strategy to develop products that test and identify specific cannabinoid isolates for targeted therapeutic purposes it has signed a binding Letter of Intent ("LOI") to acquire 65% of Biolennia Laboratories Inc. (the "Laboratory").

Biolennia will provide a host of drug testing services to support MJ BioPharma's product line and provide research and development (R&D), product formulation, extraction facilities, systems design and develop standard-operating-procedures (SOPs). The lab is currently in the process of applying for a Dealer's License from Health Canada. Once issued the license will allow the Company to process cultivated cannabis (extracts and/or derivatives) for R&D purposes.

Biolennia was founded in 2001 by Dean Swift as the internal R&D and quality testing laboratory to support Micrylium Laboratories Inc. ("Micrylium"). In 2002 it upgraded to a full active ingredient and microbial testing laboratory for several Health Canada approved products. Biolennia is a specialty development laboratory with expertise in Microbiology (bacteria, fungi, viruses), Chemistry (proteins, enzymes, drug testing, material science and analytics). The Laboratory currently provides testing, R&D and quality control for a proprietary line of Health Canada registered and approved industrial disinfectants and other consumer products on behalf of Micrlylium.

Biolennia has in-house expertise in methods accepted by Health Canada and the Federal Drug Administration (FDA) for determining purity and quality of many of the materials and methods used in validating cannabis and or testing cannabis products. Biolennia brings a highly talented team of Microbiologists who are familiar with testing high purity water, ethanol, ethyl acetate, propylene glycol, xylitol, glycerine, propandiaol, d-limonene, myrcene, and beta caryophelline."

Provider of technology platforms for the cannabis industry MassRoots Inc. (OTCQB: MSRT), has completed its acquisition in late January of DDDigtal, d.b.a. "Whaxy," an online order-ahead and menu management platform. Since launching in May 2016, Whaxy's online ordering platform has processed over $7 million in volume across 60,000 unique transactions. MassRoots mobile apps enable consumers to make educated cannabis purchasing decisions through community-drive reviews. MassRoots is proud to be affiliated with the leading businesses and organizations in the cannabis industry, including the ArcView Group and National Cannabis Industry Association.

Medical Marijuana Inc. (OTC: MJNA) subsidiary, HempMeds® Brasil announced the Brazilian government has authorized a doctor's prescription for the Company's hemp cannabidiol oil product Real Scientific Hemp Oil™ (RSHO™) to treat patients in the country suffering from Multiple Sclerosis. "We commend the Brazilian government for recognizing nationwide health problems that exist, including Multiple Sclerosis and a multitude of other chronic medical conditions, and looking for solutions that can help alleviate those problems," said Medical Marijuana, Inc. CEO, Dr. Stuart Titus. "Brazil has embraced the therapeutic value of medical cannabinoids and is helping its people treat the symptoms of certain conditions with no known cure or limited treatment options."

MCig Inc. (OTCQB: MCIG) is a diversified company servicing the legal cannabis, hemp, and cannabidiol markets via its lifestyle brands. The company has transitioned from a vaporizer manufacturer to industry leading large scale, full service cannabis cultivation Construction Company with its Grow Contractors division currently operating in the rapidly expanding Nevada market. The company looks forward to growing its core competencies to service the Ancillary legal Cannabis, Hemp, and CBD markets, with broader expansion to take place once federal laws change.

Crown Baus Capital Corporation announces the Company had acquired a 100-acre investment participation in the Cannabis Science Inc. (OTC: CBIS) Property and Drug Development Projects spread across California and Nevada. In this agreement, it includes cultivation, laboratory, and manufacturing capabilities. "I am excited to announce our agreement with CBIS. That's 66,000 sq. ft. we will be building out with CBIS & CBCA over this spring and summer. We are certainly looking to bring that number well over 100,000 sq. ft. over the coming months. In line with CBCA's growth strategy in one of our core areas, we see tremendous value in our Property and Drug Development Projects. Each one-acre parcel provides investors with 33,000 square feet of space to build fully-licensed and state compliant medical cannabis and/or industrial hemp production facilities," said President and Chief Executive Officer of both Crown Baus Capital and Cannabis Science, Raymond C. Dabney.